Abstract
The activity in vitro of clarithromycin, a new macrolide, was compared to that of various antibiotics in tests using 3,880 clinical isolates. Clarithromycin was two times more active than erythromycin againstStaphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, streptococci of groups C, G and F,Brucella melitensis, Legionella pneumophila andMycoplasma spp., 16 times more active againstUreaplasma urealyticum and 2 to 4 times less active againstCampylobacter spp. In general, clarithromycin showed intrinsic activity 2 to 4 times higher than that of roxithromycin and 4 to 8 times higher than that of miocamycin. Cross-resistance was found between the macrolides. Clarithromycin was bactericidal againstStreptococcus spp. andHaemophilus influenzae.
Similar content being viewed by others
References
Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernandes PB Comparative in vitro activity of new 14-, 15-, and 16-membered macrolides. Antimicrobial Agents and Chemotherapy 1988, 32: 1710–1719.
Brittain DC Erythromycin. Medical Clinics of North America 1987, 71: 1147–1154.
Fernandes PB, Bailer R, Swanson R, Hanson CW, McDonald E, Ramer N, Hardy D, Shipkowitz N, Bower RR, Gade E In vitro and in vivo evaluation of A-56268 (TE-031) a new macrolide. Antimicrobial Agents and Chemotherapy 1986, 30: 865–873.
National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2nd edition. Approved standard. Document M7-A1. NCCLS, Villanova, PA, 1990.
National Committee for Clinical Laboratory Standards Methods for antimicrobial susceptibility testing of anaerobic bacteria, 2nd edition. Tentative standard. Document M11-T2. NCCLS, Villanova, PA, 1989.
National Committee for Clinical Laboratory Standards Methods for determining bactericidal activity of antimicrobial agents. Proposed Guideline. Document M26-P. NCCLS, Villanova, PA, 1987.
Benson CA, Segreti J, Beaudette FE, Hines DW, Goodman LJ, Kaplan RL, Trenholme GM In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms. Antimicrobial Agents and Chemotherapy 1987, 31: 328–330.
Chin NX, Neu NM, Labthavikul P, Saha G, Neu HC Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. Antimicrobial Agents and Chemotherapy 1987, 31: 463–466.
Fernandes PB, Hardy DJ Comparative in vitro potencies of nine new macrolides. Drugs under Experimental and Clinical Research 1988, 7: 445–451.
Floyd-Reising S, Hindler JA, Young LS In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents. Antimicrobial Agents and Chemotherapy 1987, 31: 640–642.
Hodinka RL, Jack-Wait K, Gilligan PH Comparative in vitro activity of A-56268 (TE-031), a new macrolide antibiotic. European Journal of Clinical Microbiology 1987, 6: 103–108.
Jorgensen JH, Maher LA, Howell AW Activity of clarithromycin and its principal human metabolite againstHaemophilus influenzae. Antimicrobial Agents and Chemotherapy 1991, 35: 1524–1526.
Lorian V, Sabath LD Effect of pH on the activity of erythromycin against 500 isolates of gram-negative bacilli. Applied Microbiology 1970, 20: 754–756.
Author information
Authors and Affiliations
Consortia
Additional information
M. Rodríguez Creixems, E. Bouza, Hospital Gregorio Marañón, Madrid. F. Soriano, Fundación Jiménez Díaz, Madrid. D. Dámaso, Clínica Puerta de Hierro, Madrid. J. Liñares, Hospital Príncipes de España, Barcelona. J. García de Lomas, Hospital Universitario, Valencia. M. Gobernado, Hospital La Fe, Valencia. F. Martín Luengo, Hospital Universitario, Murcia. E. Perea, Hospital Universitario, Sevilla. J.A. García Rodríguez, Hospital Universitario, Salamanca, R. Gómez Lus, Hospital Universitario, Zaragoza.
Rights and permissions
About this article
Cite this article
Loza, E., Martínez Beltrán, J., Baquero, F. et al. Comparative in vitro activity of clarithromycin. Eur. J. Clin. Microbiol. Infect. Dis. 11, 856–866 (1992). https://doi.org/10.1007/BF01960892
Issue Date:
DOI: https://doi.org/10.1007/BF01960892